57 results
8-K
EX-10.1
OCUP
Ocuphire Pharma Inc
17 Apr 24
Departure of Directors or Certain Officers
4:23pm
, to perform the Services. Consultant will be free of control and direction from the Company (other than general oversight and control over the scope of work
424B5
OCUP
Ocuphire Pharma Inc
14 Aug 23
Prospectus supplement for primary offering
8:00am
to these clinical restrictions and additional oversight by the FDA. In addition, the findings in the toxicology studies could impact the NDA reviews
8-K
EX-10.1
v941y dcahclln5c
11 Aug 23
Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update
9:27am
8-K
EX-10.1
au6eh
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm
424B5
xpq 71ev5o6
7 Jun 21
Prospectus supplement for primary offering
4:21pm
8-K/A
EX-10.1
hncnjo
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm
8-K
EX-10.1
jnzy1
4 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:48pm
424B5
1jpo5vz0
11 Mar 21
Prospectus supplement for primary offering
9:19am
8-K
EX-1.1
795 an90afm
11 Mar 21
Entry into a Material Definitive Agreement
8:34am
424B4
4jcg34 k5
17 Feb 21
Prospectus supplement with pricing info
7:14am